Original title: [Chairman of Kexon Biotech: The COVID-19 vaccine developed by the company may be marketed before the end of the year] Source: Gelonghui

Gelonghui, September 25 | Yin Weidong, Chairman and CEO of Kexon Biotech, said that the inactivated COVID-19 vaccine CoronaVac developed by the company can identify different COVID-19 strains found in various countries. After vaccination, human immunity is maintained for at least six months, and the vaccine may be marketed before the end of the year.